Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

415 Press Releases
DateTitleCompany
05 Apr 17 Boehringer Ingelheim: A New World Leader in Animal Health Boehringer Ingelheim,
Published by
Business Wire
30 Mar 17 Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries Boehringer Ingelheim,
Published by
PharmiWeb.com
30 Mar 17 Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries Boehringer Ingelheim,
Published by
PR Newswire
28 Mar 17 Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease - IPF - in Honor of his Dad Boehringer Ingelheim,
Published by
PR Newswire
21 Mar 17 Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation Boehringer Ingelheim Pharmaceuticals,
Published by
PharmiWeb.com
21 Mar 17 Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases Boehringer Ingelheim ,
Published by
PharmiWeb.com
20 Mar 17 Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases Boehringer Ingelheim,
Published by
Business Wire
20 Mar 17 Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation Boehringer Ingelheim,
Published by
Business Wire
02 Mar 17 Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers Boehringer Ingelheim,
Published by
Business Wire
27 Feb 17 Real-World Data from Boehringer Ingelheim Show Lower Risk of Stroke and Major Bleeding for Pradaxa® (dabigatran etexilate mesylate) Compared to Warfarin Boehringer Ingelheim ,
Published by
PharmiWeb.com
16 Feb 17 US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children Boehringer Ingelheim,
Published by
Business Wire
15 Feb 17 Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments Boehringer Ingelheim,
Published by
Business Wire
18 Jan 17 Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review Boehringer Ingelheim,
Published by
PR Newswire
02 Jan 17 Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017 Boehringer Ingelheim,
Published by
Business Wire
15 Dec 16 BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S. Eli Lilly and Company; Boehringer Ingelheim,
Published by
PR Newswire
08 Dec 16 Boehringer Ingelheim Awarded Perfect Score for Workplace Equality for the LGBT Community Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
07 Dec 16 Limited improvement in EGFR testing rates observed in new survey with approximately one in five advanced lung cancer patients still at risk of missing out on targeted therapy Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
29 Nov 16 Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss Boehringer Ingelheim ,
Published by
PharmiWeb.com
18 Oct 16 Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
22 Nov 16 Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes Boehringer Ingelheim and Eli Lilly and Company,
Published by
PR Newswire
25 Oct 16 Efficacy of Ofev® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST Boehringer Ingelheim,
Published by
PharmiWeb.com
26 Oct 16 Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study Boehringer Ingelheim,
Published by
PharmiWeb.com
29 Sep 16 Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
30 Sep 16 Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Oct 16 Boehringer Ingelheim Named One of Science Magazine's Top Employers for the Twelfth Consecutive Year Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
09 Oct 16 Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
09 Oct 16 Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO Boehringer Ingelheim,
Published by
PR Newswire
24 Oct 16 New Real-World Data Show Pradaxa® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment Boehringer Ingelheim ,
Published by
PharmiWeb.com
21 Oct 16 New Real-World Data Show Pradaxa® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
12 Oct 16 New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.